Invitrogen™ Miptenalimab Recombinant Monoclonal Antibody

Miptenalimab, also known as BI 754111, is a humanized IgG4 monoclonal antibody that targets the lymphocyte-activation gene 3 (LAG-3). It functions as an immune checkpoint inhibitor designed to treat various cancers, including solid tumors, head and neck cancer, and non-small cell lung cancer. Lymphocyte Activation Gene 3 (LAG3), also known as CD223, is an immune checkpoint receptor encoded by the LAG3 gene located on chromosome 12 (12p13.32). Structurally, LAG3 is closely related to the CD4 molecule, sharing four extracellular immunoglobulin-like domains and a highly conserved cytoplasmic tail, which mediates its inhibitory signaling. Functionally, LAG3 is expressed on activated T cells, natural killer (NK) cells, B cells, and plasmacytoid dendritic cells, playing a crucial role in regulating the immune response. It acts by binding to its primary ligand, MHC class II molecules, and can also interact with other ligands such as fibrinogen-like protein 1 and galectin-3. Through these interactions, LAG3 transmits inhibitory signals to reduce the proliferation and activation of effector T cells, thus maintaining immune homeostasis and preventing autoimmunity. In cancer, LAG3 contributes to the immune evasion of tumors by suppressing anti-tumor T cell activity, making it a significant target for novel cancer immunotherapies.